Salazosulfapyridine-induced angioimmunoblastic lymphadenopathy.
A 20-year-old man with ulcerative colitis was admitted because of fever, eruption and lymphadenopathy. He had started taking salazosulfapyridine one month previously. Lymph node biopsy revealed angioimmunoblastic lymphadenopathy. Autoantibody titers were all negative, and viral antibody titers were not increased retrospectively. Rearrangement of T-cell receptor beta and chromosomal aberration were not seen on the lymph node. This case is considered not to be a peripheral T-cell lymphoma but rather salazosulfapyridine-induced angioimmunoblastic lymphadenopathy (AIL), which is the second case in English language literature.
Nakano
A
A
Department of Comprehensive Care, Tenri Hospital.
Hatta
K
K
Kobashi
Y
Y
Goto
M
M
Imanaka
T
T
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D005765:Gastrointestinal Agents; D012460:Sulfasalazine; D011239:Prednisolone; D008775:Methylprednisolone